US generic competition begins to eat away at Eisai's figures
This article was originally published in Scrip
Executive Summary
In common with its Japanese peers Takeda and Astellas, Eisai is having to come to grips with the effect of US generic competition on its top products, in its case the Alzheimer's disease drug Aricept (donepezil).